Bayer and DAIICHI SANKYO Healthcare Announce Licensing Agreement for Claritin®EX

Bayer Yakuhin, Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Ashraf El Ahouf; hereinafter "Bayer") and DAIICHI SANKYO Healthcare Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President: Takahiro Uchida; hereinafter "DAIICHI SANKYO Healthcare") announce the signing of a licensing agreement for Claritin®EX, Bayer's second-class pharmaceutical for allergic rhinitis. The sales collaboration under this agreement will commence on July 1, 2024.

Regarding Claritin®EX to be sold by DAIICHI SANKYO Healthcare in Japan under this agreement, there will be no changes to the formulation, indications, dosage instructions, or manufacturer's suggested retail price. Further details on launch date and product specifications will be announced separately.

About Claritin®EX

Claritin®EX is a second-generation antihistamine containing the active ingredient loratadine. It includes components known for their low drowsiness potential and helps relieve symptoms of allergic rhinitis—including sneezing, runny nose, and nasal congestion—commonly caused by hay fever. With once-daily dosing of one tablet, its effects last throughout the day, reducing the likelihood of missed doses. Backed by its global track record as a widely used non-sedating allergy treatment, Claritin®EX has long supported improved quality of life (QOL) for consumers in Japan.

Background and Purpose of the Sales Partnership

Bayer possesses global expertise in the healthcare sector and extensive experience in enhancing the value of Claritin®EX. Through this partnership, Bayer will collaborate with DAIICHI SANKYO Healthcare’s expertise in the OTC pharmaceutical market and its nationwide distribution network to ensure Claritin®EX reaches patients more effectively, contributing to the further development of self-care in Japan’s allergy treatment landscape.

DAIICHI SANKYO Healthcare has previously focused on key OTC pharmaceutical categories, offering allergy-specific nasal sprays and eye drops. By adding the oral medication Claritin®EX to its product lineup, the company aims to strengthen its presence in the allergy care segment. Nasal allergies, characterized by uncomfortable symptoms such as sneezing, runny nose, and congestion, are a common health concern affecting many individuals—especially during pollen season. In recent years, the social impact of allergies has also been increasingly recognized. Leveraging its experience in pharmaceutical sales and consumer information dissemination, DAIICHI SANKYO Healthcare will continue to support an environment where individuals can make informed, appropriate choices and use medications responsibly as part of self-care and self-medication initiatives.

Through this partnership, both companies aim to deliver Claritin®EX to a broader audience suffering from nasal allergy symptoms and contribute to advancing self-care and self-medication in the field of allergy management, particularly for pollen-related conditions.

<Reference>

### ■ About DAIICHI SANKYO Healthcare

DAIICHI SANKYO Healthcare is growing as a total healthcare company, expanding from its leadership in the OTC pharmaceutical market into functional skincare, oral care, and food sectors, all aimed at supporting healthier lives.

The company’s corporate slogan, “Fit for You – A Life Partner for Everyone’s Healthy Life,” reflects its mission to contribute to a society where everyone can confidently practice self-care and self-medication.

### ■ About Bayer

Through its prescription pharmaceuticals and consumer health businesses, Bayer is committed to sustainable initiatives that transform treatment for patients in Japan. In the prescription segment, the company focuses on specialty areas with high unmet medical needs—such as cardiovascular, renal, metabolic, oncology, and ophthalmology—and diagnostic imaging, striving to extend healthy life expectancy and improve QOL for Japan’s aging population through innovative medicines. In consumer health, Bayer focuses on nutritional supplements that support women from pre-pregnancy through pregnancy, postpartum, and lactation, ensuring proper nutrition during the “first 1,000 days” of a baby’s life. For more information, visit www.pharma.bayer.jp, Facebook, or YouTube.